Key result
Higher serum ANGPTL3 levels were independently associated with peripheral arterial stiffness in patients with coronary artery disease (OR 1.004; 95% CI 1.000-1.007; p=0.041).
Why the study?
ANGPTL3 regulates lipid metabolism, but its relationship with peripheral arterial stiffness in patients with CAD required evaluation.
Is serum ANGPTL3 level associated with peripheral arterial stiffness in patients with coronary artery disease?
Cross-Sectional (n=95)
Is serum ANGPTL3 level associated with peripheral arterial stiffness in patients with coronary artery disease?
Higher serum ANGPTL3 levels are independently associated with increased peripheral arterial stiffness in patients with coronary artery disease.
Answers are grounded in this paper and cite their sources.
Serum ANGPTL3 may flag higher PAS risk in CAD; leaves open prospective validation before clinical adoption.
Background and Objectives: Angiopoietin-like protein 3 (ANGPTL3) is a secretory protein regulating lipid metabolism. This study evaluated the relationship between serum ANGPTL3 level and peripheral arterial stiffness (PAS) in patients with coronary artery disease (CAD). Materials and Methods: Fasting blood samples were collected from 95 CAD patients. PAS was defined as left or right brachial-ankle pulse wave velocity (baPWV) > 18.0 m/s by an oscillometric method. Serum ANGPTL3 levels were assessed using a commercial enzyme-linked immunosorbent assay kit. Results: Seventeen CAD patients (17.9%) had PAS. Patients with PAS had a significantly higher percentage of diabetes (p = 0.002), older age (p = 0.030), higher systolic blood pressure (p = 0.016), higher fasting glucose (p = 0.008), serum C-reactive protein (p = 0.002), and ANGPTL3 level (p = 0.001) than those without PAS. After multivariable logistic regression analysis, serum ANGPTL3 level (Odds ratio (OR): 1.004, 95% confidence interval (CI): 1.000–1.007, p = 0.041) is still independently associated with PAS in CAD patients. The receiver operating characteristic curve for PAS prediction revealed that the area under the curve for ANGPTL3 level was 0.757 (95% CI: 0.645–0.870, p < 0.001). Conclusions: Serum fasting ANGPTL3 level is positively associated with PAS in CAD patients. Further studies are required for clarification.
No takes yet. Share an insight, caveat, or question.
Hsiao et al. (2021) conducted a cross-sectional in Coronary artery disease (n=95). Serum ANGPTL3 level vs. Lower ANGPTL3 level was evaluated on Peripheral arterial stiffness (PAS) (OR 1.004, 95% CI 1.000-1.007, p=0.041). Higher serum ANGPTL3 levels were independently associated with peripheral arterial stiffness in patients with coronary artery disease (OR 1.004; 95% CI 1.000-1.007; p=0.041).
Synapse has enriched 10 related papers. Consider them for comparative context: